Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-06-18
2009-10-06
Nickol, Gary B. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S005000, C435S040500, C424S009100, C424S130100, C424S139100
Reexamination Certificate
active
07598046
ABSTRACT:
The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.
REFERENCES:
patent: 5134121 (1992-07-01), Mobley
patent: 5276059 (1994-01-01), Caughey et al.
patent: 5948763 (1999-09-01), Soto-Jara et al.
patent: 6022683 (2000-02-01), Poirier
patent: 6197972 (2001-03-01), Heeres et al.
patent: 6355610 (2002-03-01), Chesebro et al.
patent: 6369075 (2002-04-01), Ruggeri et al.
patent: 6462171 (2002-10-01), Soto-Jara et al.
patent: 2002/0128175 (2002-09-01), Anantharamaiah
patent: 2002/0154426 (2002-10-01), Lang et al.
patent: 2004/0018554 (2004-01-01), Green
patent: 97/14437 (1997-04-01), None
patent: 99/15159 (1999-04-01), None
patent: 01/68710 (2001-09-01), None
patent: 02/04954 (2002-01-01), None
patent: 02/065133 (2002-08-01), None
patent: 03/002533 (2003-01-01), None
patent: 03/005037 (2003-01-01), None
patent: 03/045921 (2003-06-01), None
patent: 2004/043403 (2004-05-01), None
Zerr et al (1996) Arch. Neurol. 53(12): 1233-8.
Namba et al (1991) Brain Res. 541(1): 163-6.
Naslavsky et al (1997) J Biol Chem. 272(10): 6324-31.
Soto et al (2002) Trends Neurosci. Aug.;25(8):390-4.
Huang et al (2001) Proc Natl Acad Sci U S A. Jul. 17;98(15):8838-43.
Baumann et al (2000) Biochem J. Jul. 1;349(Pt 1):77-84.
Lingappa, V.R. et al.: “Translocations Pausing and the Regulation of Membrane Protein Biogenesis” Membrane Proteins: Structure, Function and Expression Control Kyushu University Press; S. Karger AG, & International Symposium, pp. 93-100 (XP001183818) 1997.
Clavey, V. et al.: “Interaction entre le LDL-recepteur et les Lipoproteines Contenant de l'Apo B”/“Interaction Between the LDL Receptor and the Lipoproteins Containing APOB”, Annales D'Endocrinologie, Masson, Paris, France; vol. 52, pp. 459-463 (XP001029970), 1991.
Baumann, Marc H. et al.: “Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides” Biochemical Journal, (XP002262330), vol. 349, pp. 77-84, 2000.
Diedrich, Jane F. et al.: “Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E—and cathepsin D in astrocytes” Journal of Virology (XP000443989), vol. 65, No. 9, pp. 4759-4768, Sep. 1991.
Choe, Leila H. et al.: “Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease” Electrophoresis (XP002262331), vol. 23, No. 14, pp. 2242-2246, 2002.
Golaz, Olivier et al.: “Phenotyping of apolipoprotein E using immobilized pH gradient gels for one-dimensional and two-dimensional separations” Electrophoresis (XP009021630), vol. 16, No. 7, pp. 1184-1186, 1995.
Lucassen, Ralf et al.: “In Vitro Amplification of Protease-Resistant Prion Protein Requires Free Sulfhydryl Groups” Biochemistry (XP002262517) vol. 42, No. 14, pp. 4127-4135, 2003.
Enari, M. et al.: “Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody”, Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington, US, vol. 98, No. 16, pp. 9295-9299 (XP002959455) Jul. 31, 2001.
Schulz-Schaeffer, Walter J. et al.: “The Paraffin-Embedded Tissue Blot Detects PrPScEarly in the Incubation Time in Prion Diseases”, American Journal of Pathology (XP002262332) vol. 156, No. 1, pp. 51-56, Jan. 2000.
Korth, C. et al.: “Prion (PrSc)-specific epitope defined by a monoclonal antibody” Nature, MacMillan Journals Ltd. London, GB (XP002069611) vol. 390, pp. 74-77, Nov. 6, 1997.
Aizawa, Yuji et al.: “Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease” Brain Research vol. 768, pp. 208-214, 1997.
Baron, Gerald S. et al.: “Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrPSc) into contiguous membranes” The EMBO Journal vol. 21, No. 5, pp. 1031-1040, 2002.
Bruce, M.E. et al.: “Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent” Nature, vol. 389, pp. 498-501, Oct. 2, 1997.
Bueler, H. et al.: “Mice Devoid of Prp Are Resistant to Scrapie” Cell vol. 73, pp. 1339-1347, Jul. 2, 1983.
Chabry, Joelle et al.: “Specific Inhibition of in Vitro Formation of Protease-resistant Prion Protein by Synthetic Peptides” The Journal of Biological Chemistry, vol. 273, No. 21, pp. 13203-13207, May 22, 1998.
Choi, Sungshin Y. et al.: “Dissociation of LPL and LDL: effects of lipoproteins and anti-apoB antibodies” Journal of Lipid Research, vol. 38, pp. 77-85, 1997.
Cohen, Fred E. et al.: “Pathologic Conformations of Prion Proteins” Annu. Rev. Biochem., vol. 67, pp. 793-819, 1998.
Fantini, Jacques et al.: “Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases” Expert Reviews in Molecular Medicine, pp. 1-22, Dec. 20, 2002.
Hooper, Nigel M.: “Detergent-insoluble glycosphingolipid/cholesterol-rich membraane domains, lipid rafts and caveolae (Review)”, Molecular Membrane Biology, vol. 16, pp. 145-156, 1999.
Pan, Keh-Ming et al.: “Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins” Proc. Natl. Acad. Sci. USA, vol. 90, pp. 10962-10966, Dec. 1993.
Prusiner, Stanley B.: “Molecular Biology of Prion Diseases” Science, vol. 252, pp. 1515-1522, Jun. 14, 1991.
Prusiner, Stanley B.: “Prions” Proc. Natl. Acad. Sci. USA, vol. 95, pp. 13363-13383, Nov. 1998.
Roos, Raymond et al.: “The Clinical Characteristics of Trasnmissible Creutzfeldt-Jakob Disease” Brain, vol. 96, pp. 1-20, 1973.
Saborio, Gabriela P. et al.: “Cell-Lysate Conversion of Prion Protein into Its Protease-Resistant Isoform Suggest the Participation of a Cellular Chaperone” Biochemical and Biophysical Research Communications, vol. 258, pp. 470-475, 1999.
Saborio, Gabriela P. et al.: “Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding”, Nature, vol. 411, pp. 810-813, Jun. 14, 2001.
Segrest, Jere P. et al.: “Structure of apolipoprotein B-100 in low density lipoproteins” Journal of Lipid Research, vol. 42, pp. 1346-1367, 2001.
Simons, Kai et al.: “Lipid Rafts and Signal Transduction” Molecular Cell Biology, vol. 1, pp. 31-41, Oct. 2000.
Scott, Michael R. et al.: “Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans” Proc. Natl. Acad. Sci. USA, vol. 96, No. 26, pp. 15137-15142, Dec. 21, 1999.
Soto, Claudio et al.: “Prions: disease propagation and disease therapy by conformational transmission” Trends in Molecular Medicine, vol. 7, No. 3, pp. 109-114, Mar. 2001.
Taraboulos, Albert et al.: “Cholesterol Depletion and Modification of COOH-Terminal Targeting Sequence of the Prion Protein Inhibit Formation of the Scrapie Isoform” The Journal of Cell Biology, vol. 129, No. 1, pp. 121-132, Apr. 1995.
Telling, Glenn C. et al.: “Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein” Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9936-9940, Oct. 1994.
Tsui-Pierchala, Brian A. et al.: “Lipid rafts in neuronal signaling and function” Trends in Neurosciences, vol. 25, N
Maundrell Kinsey
Soto-Jara Claudio
Horning Michelle
Laboratories Serono SA
Nickol Gary B.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Use of prion conversion modulating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of prion conversion modulating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of prion conversion modulating agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4120648